In the From the Food and Drug Administration column published in the
February 4, 1998, issue of THE JOURNAL (1998;279:346), there was incorrect
wording under the heading "Two New Warnings Added to Labeling for Mibefradil."
Mibrefadil is not contraindicated for patients concurrently receiving fluvastatin.
The 2 drugs for which a new warning states that concurrent use with Mibefradil
is contraindicated are lovastatin and simvastatin.
Incorrect Wording. JAMA. 1998;279(12):913. doi:10.1001/jama.279.12.913